Post-earnings recap
Reported
Thu, Aug 8, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Nektar Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 2.67%. The absence of revenue figures and guidance may leave some investors cautious, but the EPS beat indicates potential operational improvements. The management's focus on R&D suggests they are prioritizing long-term growth despite current uncertainties.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.63 | N/A | +18.73% |
| Revenue | N/A | N/A | N/A |
Management appears cautiously optimistic about the company's direction. They emphasized their commitment to advancing their pipeline, although specific revenue guidance was not provided.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing efforts in research and development as a priority.